English
简体中文
Total: £ 56.28
Published Date: 2025-11-12 | Pages: 165 | Tables: 165 | Medical Care
The global Targeted Protein Degrader Technology market is projected to grow from US$ 102 million in 2024 to US$ 363 million by 2031, at a CAGR of 18.3% (2025-2031), driven by critical product segments and diverse end‑use applications.
Targeted protein degradation technology involves the design and development of small molecules or biologics that selectively bind to specific proteins within cells and mark them for degradation by the cell's natural protein degradation machinery, such as the ubiquitin-proteasome system or lysosomes. This approach enables the removal of disease-causing or undesirable proteins, including those considered "undruggable" by traditional small molecule inhibitors, by harnessing the body's own degradation pathways. Typically, targeted protein degraders consist of a ligand that binds to the target protein, a linker, and a component that recruits the cellular degradation machinery. This technology holds promise for the treatment of various diseases, including cancer and genetic disorders, by targeting proteins involved in disease pathways with high specificity and efficacy.
Targeted protein degradation (TPD) technology is experiencing rapid growth and increasing interest across the biopharmaceutical industry, driven by its ability to address previously "undruggable" targets and offer novel therapeutic strategies for cancer, neurodegenerative diseases, and autoimmune disorders. The market is characterized by a surge in strategic partnerships, licensing deals, and R&D investments from both established pharmaceutical companies and emerging biotech firms. Key technological platforms—such as PROTACs (proteolysis-targeting chimeras), molecular glues, and autophagy-based degraders—are progressing through clinical pipelines, with several candidates entering early-phase trials. As the field matures, advancements in degrader design, improved target specificity, and favorable regulatory developments are expected to accelerate adoption and expand therapeutic applications.
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Targeted Protein Degrader Technology market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Arvinas
C4 Therapeutics
Kymera Therapeutics
Nurix
Pfizer
Novartis
MSD
Foghorn Therapeutics
Dialectic Therapeutics
Accutar Biotech
Cullgen
Bristol-Myers Squibb
Monte Rosa Therapeutics
Proxygen
Dunad Therapeutics
Astellas
Origami Therapeutics
NEOsphere Biotechnologies
Ubiquigent
Kangpu Biopharmaceuticals
Ranok Therapeutics
BeiGene
Hinova Pharma
Haisco Pharmaceutical
CTTQ
Segment by Type
PROTAC
Molecular Glues
Other Ubiquitin-Proteasome System Technologies
Lysosomal System Technologies
Segment by Application
Prostate Cancer
Breast Cancer
Lymphoma
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Targeted Protein Degrader Technology study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Targeted Protein Degrader Technology: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Targeted Protein Degrader Technology Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 PROTAC
1.2.3 Molecular Glues
1.2.4 Other Ubiquitin-Proteasome System Technologies
1.2.5 Lysosomal System Technologies
1.3 Market Segmentation by Application
1.3.1 Global Targeted Protein Degrader Technology Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Prostate Cancer
1.3.3 Breast Cancer
1.3.4 Lymphoma
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Targeted Protein Degrader Technology Revenue Estimates and Forecasts 2020-2031
2.2 Global Targeted Protein Degrader Technology Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Targeted Protein Degrader Technology Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Targeted Protein Degrader Technology Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 PROTAC Market Size by Players
3.3.2 Molecular Glues Market Size by Players
3.3.3 Other Ubiquitin-Proteasome System Technologies Market Size by Players
3.3.4 Lysosomal System Technologies Market Size by Players
3.4 Global Targeted Protein Degrader Technology Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Targeted Protein Degrader Technology Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Targeted Protein Degrader Technology Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Targeted Protein Degrader Technology Market Size by Type (2020-2031)
6.4 North America Targeted Protein Degrader Technology Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Targeted Protein Degrader Technology Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Targeted Protein Degrader Technology Market Size by Type (2020-2031)
7.4 Europe Targeted Protein Degrader Technology Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Targeted Protein Degrader Technology Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Targeted Protein Degrader Technology Market Size by Type (2020-2031)
8.4 Asia-Pacific Targeted Protein Degrader Technology Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Targeted Protein Degrader Technology Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Targeted Protein Degrader Technology Market Size by Type (2020-2031)
9.4 Central and South America Targeted Protein Degrader Technology Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Targeted Protein Degrader Technology Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Targeted Protein Degrader Technology Market Size by Type (2020-2031)
10.4 Middle East and Africa Targeted Protein Degrader Technology Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Targeted Protein Degrader Technology Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Arvinas
11.1.1 Arvinas Corporation Information
11.1.2 Arvinas Business Overview
11.1.3 Arvinas Targeted Protein Degrader Technology Product Features and Attributes
11.1.4 Arvinas Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.1.5 Arvinas Targeted Protein Degrader Technology Revenue by Product in 2024
11.1.6 Arvinas Targeted Protein Degrader Technology Revenue by Application in 2024
11.1.7 Arvinas Targeted Protein Degrader Technology Revenue by Geographic Area in 2024
11.1.8 Arvinas Targeted Protein Degrader Technology SWOT Analysis
11.1.9 Arvinas Recent Developments
11.2 C4 Therapeutics
11.2.1 C4 Therapeutics Corporation Information
11.2.2 C4 Therapeutics Business Overview
11.2.3 C4 Therapeutics Targeted Protein Degrader Technology Product Features and Attributes
11.2.4 C4 Therapeutics Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.2.5 C4 Therapeutics Targeted Protein Degrader Technology Revenue by Product in 2024
11.2.6 C4 Therapeutics Targeted Protein Degrader Technology Revenue by Application in 2024
11.2.7 C4 Therapeutics Targeted Protein Degrader Technology Revenue by Geographic Area in 2024
11.2.8 C4 Therapeutics Targeted Protein Degrader Technology SWOT Analysis
11.2.9 C4 Therapeutics Recent Developments
11.3 Kymera Therapeutics
11.3.1 Kymera Therapeutics Corporation Information
11.3.2 Kymera Therapeutics Business Overview
11.3.3 Kymera Therapeutics Targeted Protein Degrader Technology Product Features and Attributes
11.3.4 Kymera Therapeutics Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.3.5 Kymera Therapeutics Targeted Protein Degrader Technology Revenue by Product in 2024
11.3.6 Kymera Therapeutics Targeted Protein Degrader Technology Revenue by Application in 2024
11.3.7 Kymera Therapeutics Targeted Protein Degrader Technology Revenue by Geographic Area in 2024
11.3.8 Kymera Therapeutics Targeted Protein Degrader Technology SWOT Analysis
11.3.9 Kymera Therapeutics Recent Developments
11.4 Nurix
11.4.1 Nurix Corporation Information
11.4.2 Nurix Business Overview
11.4.3 Nurix Targeted Protein Degrader Technology Product Features and Attributes
11.4.4 Nurix Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.4.5 Nurix Targeted Protein Degrader Technology Revenue by Product in 2024
11.4.6 Nurix Targeted Protein Degrader Technology Revenue by Application in 2024
11.4.7 Nurix Targeted Protein Degrader Technology Revenue by Geographic Area in 2024
11.4.8 Nurix Targeted Protein Degrader Technology SWOT Analysis
11.4.9 Nurix Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Targeted Protein Degrader Technology Product Features and Attributes
11.5.4 Pfizer Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.5.5 Pfizer Targeted Protein Degrader Technology Revenue by Product in 2024
11.5.6 Pfizer Targeted Protein Degrader Technology Revenue by Application in 2024
11.5.7 Pfizer Targeted Protein Degrader Technology Revenue by Geographic Area in 2024
11.5.8 Pfizer Targeted Protein Degrader Technology SWOT Analysis
11.5.9 Pfizer Recent Developments
11.6 Novartis
11.6.1 Novartis Corporation Information
11.6.2 Novartis Business Overview
11.6.3 Novartis Targeted Protein Degrader Technology Product Features and Attributes
11.6.4 Novartis Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.6.5 Novartis Recent Developments
11.7 MSD
11.7.1 MSD Corporation Information
11.7.2 MSD Business Overview
11.7.3 MSD Targeted Protein Degrader Technology Product Features and Attributes
11.7.4 MSD Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.7.5 MSD Recent Developments
11.8 Foghorn Therapeutics
11.8.1 Foghorn Therapeutics Corporation Information
11.8.2 Foghorn Therapeutics Business Overview
11.8.3 Foghorn Therapeutics Targeted Protein Degrader Technology Product Features and Attributes
11.8.4 Foghorn Therapeutics Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.8.5 Foghorn Therapeutics Recent Developments
11.9 Dialectic Therapeutics
11.9.1 Dialectic Therapeutics Corporation Information
11.9.2 Dialectic Therapeutics Business Overview
11.9.3 Dialectic Therapeutics Targeted Protein Degrader Technology Product Features and Attributes
11.9.4 Dialectic Therapeutics Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.9.5 Dialectic Therapeutics Recent Developments
11.10 Accutar Biotech
11.10.1 Accutar Biotech Corporation Information
11.10.2 Accutar Biotech Business Overview
11.10.3 Accutar Biotech Targeted Protein Degrader Technology Product Features and Attributes
11.10.4 Accutar Biotech Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Cullgen
11.11.1 Cullgen Corporation Information
11.11.2 Cullgen Business Overview
11.11.3 Cullgen Targeted Protein Degrader Technology Product Features and Attributes
11.11.4 Cullgen Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.11.5 Cullgen Recent Developments
11.12 Bristol-Myers Squibb
11.12.1 Bristol-Myers Squibb Corporation Information
11.12.2 Bristol-Myers Squibb Business Overview
11.12.3 Bristol-Myers Squibb Targeted Protein Degrader Technology Product Features and Attributes
11.12.4 Bristol-Myers Squibb Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.12.5 Bristol-Myers Squibb Recent Developments
11.13 Monte Rosa Therapeutics
11.13.1 Monte Rosa Therapeutics Corporation Information
11.13.2 Monte Rosa Therapeutics Business Overview
11.13.3 Monte Rosa Therapeutics Targeted Protein Degrader Technology Product Features and Attributes
11.13.4 Monte Rosa Therapeutics Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.13.5 Monte Rosa Therapeutics Recent Developments
11.14 Proxygen
11.14.1 Proxygen Corporation Information
11.14.2 Proxygen Business Overview
11.14.3 Proxygen Targeted Protein Degrader Technology Product Features and Attributes
11.14.4 Proxygen Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.14.5 Proxygen Recent Developments
11.15 Dunad Therapeutics
11.15.1 Dunad Therapeutics Corporation Information
11.15.2 Dunad Therapeutics Business Overview
11.15.3 Dunad Therapeutics Targeted Protein Degrader Technology Product Features and Attributes
11.15.4 Dunad Therapeutics Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.15.5 Dunad Therapeutics Recent Developments
11.16 Astellas
11.16.1 Astellas Corporation Information
11.16.2 Astellas Business Overview
11.16.3 Astellas Targeted Protein Degrader Technology Product Features and Attributes
11.16.4 Astellas Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.16.5 Astellas Recent Developments
11.17 Origami Therapeutics
11.17.1 Origami Therapeutics Corporation Information
11.17.2 Origami Therapeutics Business Overview
11.17.3 Origami Therapeutics Targeted Protein Degrader Technology Product Features and Attributes
11.17.4 Origami Therapeutics Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.17.5 Origami Therapeutics Recent Developments
11.18 NEOsphere Biotechnologies
11.18.1 NEOsphere Biotechnologies Corporation Information
11.18.2 NEOsphere Biotechnologies Business Overview
11.18.3 NEOsphere Biotechnologies Targeted Protein Degrader Technology Product Features and Attributes
11.18.4 NEOsphere Biotechnologies Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.18.5 NEOsphere Biotechnologies Recent Developments
11.19 Ubiquigent
11.19.1 Ubiquigent Corporation Information
11.19.2 Ubiquigent Business Overview
11.19.3 Ubiquigent Targeted Protein Degrader Technology Product Features and Attributes
11.19.4 Ubiquigent Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.19.5 Ubiquigent Recent Developments
11.20 Kangpu Biopharmaceuticals
11.20.1 Kangpu Biopharmaceuticals Corporation Information
11.20.2 Kangpu Biopharmaceuticals Business Overview
11.20.3 Kangpu Biopharmaceuticals Targeted Protein Degrader Technology Product Features and Attributes
11.20.4 Kangpu Biopharmaceuticals Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.20.5 Kangpu Biopharmaceuticals Recent Developments
11.21 Ranok Therapeutics
11.21.1 Ranok Therapeutics Corporation Information
11.21.2 Ranok Therapeutics Business Overview
11.21.3 Ranok Therapeutics Targeted Protein Degrader Technology Product Features and Attributes
11.21.4 Ranok Therapeutics Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.21.5 Ranok Therapeutics Recent Developments
11.22 BeiGene
11.22.1 BeiGene Corporation Information
11.22.2 BeiGene Business Overview
11.22.3 BeiGene Targeted Protein Degrader Technology Product Features and Attributes
11.22.4 BeiGene Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.22.5 BeiGene Recent Developments
11.23 Hinova Pharma
11.23.1 Hinova Pharma Corporation Information
11.23.2 Hinova Pharma Business Overview
11.23.3 Hinova Pharma Targeted Protein Degrader Technology Product Features and Attributes
11.23.4 Hinova Pharma Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.23.5 Hinova Pharma Recent Developments
11.24 Haisco Pharmaceutical
11.24.1 Haisco Pharmaceutical Corporation Information
11.24.2 Haisco Pharmaceutical Business Overview
11.24.3 Haisco Pharmaceutical Targeted Protein Degrader Technology Product Features and Attributes
11.24.4 Haisco Pharmaceutical Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.24.5 Haisco Pharmaceutical Recent Developments
11.25 CTTQ
11.25.1 CTTQ Corporation Information
11.25.2 CTTQ Business Overview
11.25.3 CTTQ Targeted Protein Degrader Technology Product Features and Attributes
11.25.4 CTTQ Targeted Protein Degrader Technology Revenue and Gross Margin (2020-2025)
11.25.5 CTTQ Recent Developments
12 Targeted Protein Degrader TechnologyIndustry Chain Analysis
12.1 Targeted Protein Degrader Technology Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Targeted Protein Degrader Technology Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Targeted Protein Degrader Technology Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Targeted Protein Degrader Technology Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Targeted Protein Degrader Technology Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Targeted Protein Degrader Technology Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Targeted Protein Degrader Technology Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Targeted Protein Degrader Technology Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Targeted Protein Degrader Technology Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Targeted Protein Degrader Technology Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Targeted Protein Degrader Technology by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Protein Degrader Technology as of 2024)
Table 11. Global Targeted Protein Degrader Technology Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Targeted Protein Degrader Technology Companies Headquarters
Table 13. Global Targeted Protein Degrader Technology Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Targeted Protein Degrader Technology Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Targeted Protein Degrader Technology Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Targeted Protein Degrader Technology Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Targeted Protein Degrader Technology Revenue by Application (2026-2031) & (US$ Million)
Table 21. Targeted Protein Degrader Technology High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Targeted Protein Degrader Technology Growth Accelerators and Market Barriers
Table 25. North America Targeted Protein Degrader Technology Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Targeted Protein Degrader Technology Growth Accelerators and Market Barriers
Table 27. Europe Targeted Protein Degrader Technology Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Targeted Protein Degrader Technology Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Targeted Protein Degrader Technology Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Targeted Protein Degrader Technology Investment Opportunities and Key Challenges
Table 31. Central and South America Targeted Protein Degrader Technology Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Targeted Protein Degrader Technology Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Targeted Protein Degrader Technology Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Arvinas Corporation Information
Table 35. Arvinas Description and Major Businesses
Table 36. Arvinas Product Features and Attributes
Table 37. Arvinas Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Arvinas Revenue Proportion by Product in 2024
Table 39. Arvinas Revenue Proportion by Application in 2024
Table 40. Arvinas Revenue Proportion by Geographic Area in 2024
Table 41. Arvinas Targeted Protein Degrader Technology SWOT Analysis
Table 42. Arvinas Recent Developments
Table 43. C4 Therapeutics Corporation Information
Table 44. C4 Therapeutics Description and Major Businesses
Table 45. C4 Therapeutics Product Features and Attributes
Table 46. C4 Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. C4 Therapeutics Revenue Proportion by Product in 2024
Table 48. C4 Therapeutics Revenue Proportion by Application in 2024
Table 49. C4 Therapeutics Revenue Proportion by Geographic Area in 2024
Table 50. C4 Therapeutics Targeted Protein Degrader Technology SWOT Analysis
Table 51. C4 Therapeutics Recent Developments
Table 52. Kymera Therapeutics Corporation Information
Table 53. Kymera Therapeutics Description and Major Businesses
Table 54. Kymera Therapeutics Product Features and Attributes
Table 55. Kymera Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Kymera Therapeutics Revenue Proportion by Product in 2024
Table 57. Kymera Therapeutics Revenue Proportion by Application in 2024
Table 58. Kymera Therapeutics Revenue Proportion by Geographic Area in 2024
Table 59. Kymera Therapeutics Targeted Protein Degrader Technology SWOT Analysis
Table 60. Kymera Therapeutics Recent Developments
Table 61. Nurix Corporation Information
Table 62. Nurix Description and Major Businesses
Table 63. Nurix Product Features and Attributes
Table 64. Nurix Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Nurix Revenue Proportion by Product in 2024
Table 66. Nurix Revenue Proportion by Application in 2024
Table 67. Nurix Revenue Proportion by Geographic Area in 2024
Table 68. Nurix Targeted Protein Degrader Technology SWOT Analysis
Table 69. Nurix Recent Developments
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Major Businesses
Table 72. Pfizer Product Features and Attributes
Table 73. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Pfizer Revenue Proportion by Product in 2024
Table 75. Pfizer Revenue Proportion by Application in 2024
Table 76. Pfizer Revenue Proportion by Geographic Area in 2024
Table 77. Pfizer Targeted Protein Degrader Technology SWOT Analysis
Table 78. Pfizer Recent Developments
Table 79. Novartis Corporation Information
Table 80. Novartis Description and Major Businesses
Table 81. Novartis Product Features and Attributes
Table 82. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Novartis Recent Developments
Table 84. MSD Corporation Information
Table 85. MSD Description and Major Businesses
Table 86. MSD Product Features and Attributes
Table 87. MSD Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. MSD Recent Developments
Table 89. Foghorn Therapeutics Corporation Information
Table 90. Foghorn Therapeutics Description and Major Businesses
Table 91. Foghorn Therapeutics Product Features and Attributes
Table 92. Foghorn Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Foghorn Therapeutics Recent Developments
Table 94. Dialectic Therapeutics Corporation Information
Table 95. Dialectic Therapeutics Description and Major Businesses
Table 96. Dialectic Therapeutics Product Features and Attributes
Table 97. Dialectic Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Dialectic Therapeutics Recent Developments
Table 99. Accutar Biotech Corporation Information
Table 100. Accutar Biotech Description and Major Businesses
Table 101. Accutar Biotech Product Features and Attributes
Table 102. Accutar Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Accutar Biotech Recent Developments
Table 104. Cullgen Corporation Information
Table 105. Cullgen Description and Major Businesses
Table 106. Cullgen Product Features and Attributes
Table 107. Cullgen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Cullgen Recent Developments
Table 109. Bristol-Myers Squibb Corporation Information
Table 110. Bristol-Myers Squibb Description and Major Businesses
Table 111. Bristol-Myers Squibb Product Features and Attributes
Table 112. Bristol-Myers Squibb Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Bristol-Myers Squibb Recent Developments
Table 114. Monte Rosa Therapeutics Corporation Information
Table 115. Monte Rosa Therapeutics Description and Major Businesses
Table 116. Monte Rosa Therapeutics Product Features and Attributes
Table 117. Monte Rosa Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Monte Rosa Therapeutics Recent Developments
Table 119. Proxygen Corporation Information
Table 120. Proxygen Description and Major Businesses
Table 121. Proxygen Product Features and Attributes
Table 122. Proxygen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Proxygen Recent Developments
Table 124. Dunad Therapeutics Corporation Information
Table 125. Dunad Therapeutics Description and Major Businesses
Table 126. Dunad Therapeutics Product Features and Attributes
Table 127. Dunad Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Dunad Therapeutics Recent Developments
Table 129. Astellas Corporation Information
Table 130. Astellas Description and Major Businesses
Table 131. Astellas Product Features and Attributes
Table 132. Astellas Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Astellas Recent Developments
Table 134. Origami Therapeutics Corporation Information
Table 135. Origami Therapeutics Description and Major Businesses
Table 136. Origami Therapeutics Product Features and Attributes
Table 137. Origami Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Origami Therapeutics Recent Developments
Table 139. NEOsphere Biotechnologies Corporation Information
Table 140. NEOsphere Biotechnologies Description and Major Businesses
Table 141. NEOsphere Biotechnologies Product Features and Attributes
Table 142. NEOsphere Biotechnologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. NEOsphere Biotechnologies Recent Developments
Table 144. Ubiquigent Corporation Information
Table 145. Ubiquigent Description and Major Businesses
Table 146. Ubiquigent Product Features and Attributes
Table 147. Ubiquigent Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Ubiquigent Recent Developments
Table 149. Kangpu Biopharmaceuticals Corporation Information
Table 150. Kangpu Biopharmaceuticals Description and Major Businesses
Table 151. Kangpu Biopharmaceuticals Product Features and Attributes
Table 152. Kangpu Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. Kangpu Biopharmaceuticals Recent Developments
Table 154. Ranok Therapeutics Corporation Information
Table 155. Ranok Therapeutics Description and Major Businesses
Table 156. Ranok Therapeutics Product Features and Attributes
Table 157. Ranok Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 158. Ranok Therapeutics Recent Developments
Table 159. BeiGene Corporation Information
Table 160. BeiGene Description and Major Businesses
Table 161. BeiGene Product Features and Attributes
Table 162. BeiGene Revenue (US$ Million) and Gross Margin (2020-2025)
Table 163. BeiGene Recent Developments
Table 164. Hinova Pharma Corporation Information
Table 165. Hinova Pharma Description and Major Businesses
Table 166. Hinova Pharma Product Features and Attributes
Table 167. Hinova Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 168. Hinova Pharma Recent Developments
Table 169. Haisco Pharmaceutical Corporation Information
Table 170. Haisco Pharmaceutical Description and Major Businesses
Table 171. Haisco Pharmaceutical Product Features and Attributes
Table 172. Haisco Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 173. Haisco Pharmaceutical Recent Developments
Table 174. CTTQ Corporation Information
Table 175. CTTQ Description and Major Businesses
Table 176. CTTQ Product Features and Attributes
Table 177. CTTQ Revenue (US$ Million) and Gross Margin (2020-2025)
Table 178. CTTQ Recent Developments
Table 179. Raw Materials Key Suppliers
Table 180. Distributors List
Table 181. Market Trends and Market Evolution
Table 182. Market Drivers and Opportunities
Table 183. Market Challenges, Risks, and Restraints
Table 184. Research Programs/Design for This Report
Table 185. Key Data Information from Secondary Sources
Table 186. Key Data Information from Primary Sources
List of Figures
Figure 1. Targeted Protein Degrader Technology Product Picture
Figure 2. Global Targeted Protein Degrader Technology Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. PROTAC Product Picture
Figure 4. Molecular Glues Product Picture
Figure 5. Other Ubiquitin-Proteasome System Technologies Product Picture
Figure 6. Lysosomal System Technologies Product Picture
Figure 7. Global Targeted Protein Degrader Technology Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Prostate Cancer
Figure 9. Breast Cancer
Figure 10. Lymphoma
Figure 11. Others
Figure 12. Targeted Protein Degrader Technology Report Years Considered
Figure 13. Global Targeted Protein Degrader Technology Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 15. Global Targeted Protein Degrader Technology Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Targeted Protein Degrader Technology Revenue Market Share by Region (2020-2031)
Figure 17. Global Targeted Protein Degrader Technology Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. PROTAC Revenue Market Share by Player in 2024
Figure 20. Molecular Glues Revenue Market Share by Player in 2024
Figure 21. Other Ubiquitin-Proteasome System Technologies Revenue Market Share by Player in 2024
Figure 22. Lysosomal System Technologies Revenue Market Share by Player in 2024
Figure 23. Global Targeted Protein Degrader Technology Revenue Market Share by Type (2020-2031)
Figure 24. Global Targeted Protein Degrader Technology Revenue Market Share by Application (2020-2031)
Figure 25. North America Targeted Protein Degrader Technology Revenue YoY (2020-2031) & (US$ Million)
Figure 26. North America Top 5 Players Targeted Protein Degrader Technology Revenue (US$ Million) in 2024
Figure 27. North America Targeted Protein Degrader Technology Revenue (US$ Million) by Type (2020 - 2031)
Figure 28. North America Targeted Protein Degrader Technology Revenue (US$ Million) by Application (2020-2031)
Figure 29. US Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 30. Canada Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 31. Mexico Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 32. Europe Targeted Protein Degrader Technology Revenue YoY (2020-2031) & (US$ Million)
Figure 33. Europe Top 5 Players Targeted Protein Degrader Technology Revenue (US$ Million) in 2024
Figure 34. Europe Targeted Protein Degrader Technology Revenue (US$ Million) by Type (2020-2031)
Figure 35. Europe Targeted Protein Degrader Technology Revenue (US$ Million) by Application (2020-2031)
Figure 36. Germany Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 37. France Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 38. U.K. Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 39. Italy Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 40. Russia Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Targeted Protein Degrader Technology Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Top 8 Players Targeted Protein Degrader Technology Revenue (US$ Million) in 2024
Figure 43. Asia-Pacific Targeted Protein Degrader Technology Revenue (US$ Million) by Type (2020-2031)
Figure 44. Asia-Pacific Targeted Protein Degrader Technology Revenue (US$ Million) by Application (2020-2031)
Figure 45. Indonesia Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 46. Japan Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 47. South Korea Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 48. Australia Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 49. India Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 50. Indonesia Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 51. Vietnam Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 52. Malaysia Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 53. Philippines Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 54. Singapore Targeted Protein Degrader Technology Revenue (2020-2031) & (US$ Million)
Figure 55. Central and South America Targeted Protein Degrader Technology Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Central and South America Top 5 Players Targeted Protein Degrader Technology Revenue (US$ Million) in 2024
Figure 57. Central and South America Targeted Protein Degrader Technology Revenue (US$ Million) by Type (2020-2031)
Figure 58. Central and South America Targeted Protein Degrader Technology Revenue (US$ Million) by Application (2020-2031)
Figure 59. Brazil Targeted Protein Degrader Technology Revenue (2020-2025) & (US$ Million)
Figure 60. Argentina Targeted Protein Degrader Technology Revenue (2020-2025) & (US$ Million)
Figure 61. Middle East and Africa Targeted Protein Degrader Technology Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Middle East and Africa Top 5 Players Targeted Protein Degrader Technology Revenue (US$ Million) in 2024
Figure 63. South America Targeted Protein Degrader Technology Revenue (US$ Million) by Type (2020-2031)
Figure 64. Middle East and Africa Targeted Protein Degrader Technology Revenue (US$ Million) by Application (2020-2031)
Figure 65. GCC Countries Targeted Protein Degrader Technology Revenue (2020-2025) & (US$ Million)
Figure 66. Israel Targeted Protein Degrader Technology Revenue (2020-2025) & (US$ Million)
Figure 67. Egypt Targeted Protein Degrader Technology Revenue (2020-2025) & (US$ Million)
Figure 68. South Africa Targeted Protein Degrader Technology Revenue (2020-2025) & (US$ Million)
Figure 69. Targeted Protein Degrader Technology Industry Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
